Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05809596 · ClinicalTrials.gov registry record · NA
HEAL-LAA Clinical Trial
A NA study, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- NA
- Development phase
- 949
- Enrollment target
NCT05809596: Completed NA study, sponsored by Boston Scientific Corporation.
NCT05809596 is a NA study that has completed, run by Boston Scientific Corporation. The registered enrollment target is 949 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (32% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05809596, a NA study, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 949 participants
- Enrollment target
Study Summary
The primary objective of this study is to collect real-world data on WATCHMAN FLX™ Pro Left Atrial Appendage Closure (LAAC) Device in patients with non-valvular atrial fibrillation.
Primary Outcome
Incomplete seal with peri-device gap \> 5mm in the primary analysis subset implanted patients with 45-day TEE imaging (as assessed by the core lab).
Interventions
- DEVICE WATCHMAN FLX Pro LAAC Device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 949 participants |
| Start Date | 2023-10-03 |
| Est. Completion | 2025-09-18 |
| Phase | NA |
What the finished NCT05809596 record still lists
NCT05809596 is an interventional study that assigns participants to a tested intervention. The registered 949 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (32% lower).
The record links to 0 conditions, and to 1 intervention - of which WATCHMAN FLX Pro LAAC Device is the first listed.
NCT05809596 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05809596 about?
NCT05809596 is a clinical study titled "HEAL-LAA Clinical Trial". The primary objective of this study is to collect real-world data on WATCHMAN FLX™ Pro Left Atrial Appendage Closure (LAAC) Device in patients with non-valvular atrial fibrillation.
What is the current status of trial NCT05809596?
This trial is currently completed. It is a NA study. The enrollment target is 949 participants. The study started on 2023-10-03. Estimated completion is 2025-09-18.
What interventions are being tested in trial NCT05809596?
The interventions under investigation include: WATCHMAN FLX Pro LAAC Device (DEVICE).
Who is sponsoring clinical trial NCT05809596?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05809596's enrollment target sits among peer trials
949 123rd of 2000 higher than 1,878 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04895709 · 949 participants · Phase 1
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
- NCT03784924 · 950 participants
EDRN Prostate MRI Biomarker Study
- NCT04180930 · 950 participants
An Evaluation of Two PTSD Assessments in an Active Duty and Military Veteran Sample
- NCT06087224 · 947 participants · NA
The TELENEO Trial: A Multicenter Trial of Telemedicine for Advanced Neonatal Resuscitations in Community Hospitals
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI